NCT05221827终止不适用
Clinical Performance Evaluation of the C2i-Test for Detecting Molecular Residual Disease (MRD) in Bladder Cancer Patients.
C2i Genomics1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2022年2月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Overall specificity of the C2i-Test
研究概览
简要总结
The C2i-WGS-MRD Test (hereinafter referred to as C2i-Test), a personalized molecular circulating tumor DNA (ctDNA) test, is an in vitro qualitative test that uses next generation sequencing (NGS) based whole-genome sequencing (WGS) data for detecting molecular residual disease (MRD) in patients diagnosed with muscle-invasive bladder cancer (MIBC) and histopathologically classified as stage II-IIIA. The C2i-Test is a single site assay performed in the C2i Genomics' CLIA-certified laboratory. This is a prospective non-interventional study to collect definitive evidence of the safety and effectiveness of C2i-Test for the intended use, in a statistically justified number of subjects.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 22 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have clinically and pathologically confirmed diagnosis of MIBC.
- •A representative FFPE biopsy specimen (from the transurethral resection of bladder tumor - TURBT) with at least 1 H&E slide and 9 unstained slides, with an associated pathology report must be available.
- •Subjects must agree to 8mL blood collection during all visits.
- •Participants with MIBC, clinical stage II (cT2, N0) or IIIA (cT3, N0; cT4a, N0; cT1-T4a, N1) (lymph node positive if >10 mm on CT or MRI in short axis), diagnosed by work-up recommended by NCCN guidelines (including cystoscopy, abdominal/pelvic imaging that includes imaging of upper urinary tract collecting system, examination under anesthesia, TURBT, and bone imaging if clinical suspicion or symptoms of bone metastases within 4 weeks prior to enrollment, however patients can be enrolled if they are reassessed, and the localized status is reconfirmed with subsequent imaging studies).
- •Histopathologically confirmed urothelial carcinoma as diagnosed by TURBT. Variant urothelial histology (e.g., micropapillary, plasmacytoid, sarcomatoid, nested variant, lymphoepithelioid, nested variant) is acceptable. Mixed histology (adenocarcinoma, squamous cell) is acceptable if there is a predominant (>50%) urothelial component.
- •Treatment plans must include RC.
- •Participant is willing and able to comply with the protocol, including RC, pelvic lymph node dissection (PLND), and prostatectomy (if applicable).
- •The patient must be deemed appropriate for RC, PLND, and prostatectomy (if applicable) by his/her oncologist and/or urologist.
- •Patient's treatment plan may or may not include neoadjuvant treatment and/or adjuvant treatment.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Patient is willing and able to provide written informed consent for samples to be collected and used in this study.
排除标准
- •Extravesical urothelial carcinoma (UC) that invades the pelvic and/or abdominal wall for bladder cancer (T4b) as evidenced by imaging.
- •Evidence of UC in the urinary tract (ureters, renal pelvis, and urethra) as evidenced by work-up in accordance with NCCN guidelines (e.g., abdominal/pelvic imaging) that includes imaging of upper urinary tract collecting system).
- •Clinical evidence of greater than 1 positive LN (≥ 10 mm in short axis) or metastatic bladder cancer per IV contrast-enhanced CT or MRI scan and/or PET-CT scan.
- •Patients with mixed histology and <50% urothelial component as evidenced by TURBT pathology.
- •Tumors that contain any neuroendocrine/small cell component as evidenced by TURBT pathology.
- •Diagnosis of 3 or more synchronous cancers.
- •Malignancies other than urothelial cancer within 5 years prior to study entry except those with negligible risk of metastases or death and treated with the expectation of curative outcome (such as: carcinoma in situ of the cervix, basal or squamous cell skin cancer, ductal carcinoma in situ treated surgically with curative intent, papillary thyroid carcinoma, localized prostate cancer treated with curative intent and absence of prostate-specific antigen (PSA) relapse, or incidental prostate cancer [Gleason score ≤ 3 + 4 and PSA < 10 ng/mL] undergoing active surveillance and treatment naïve).
- •Prior chemotherapy or immunotherapy, radiation therapy, or surgery other than TURBT for bladder cancer.
- •Per physician discretion: patients with severe or uncontrolled concomitant medical, surgical, or psychiatric disease that could affect compliance with the protocol, the results of the study, or interpretation of the results.
- •Individuals who cannot provide consent for their own participation will not be included.
- •Sponsors employees and their family.
结局指标
主要结局
Overall specificity of the C2i-Test
时间窗: 3-year
Predicting 3-year recurrence-free survival post- definitive treatment (RC/RC + adjuvant chemotherapy), compared to the GS diagnosis as determined by patient outcome (based on NCCN guidelines).
次要结局
- Overall sensitivity of the C2i-Test(3-year)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyMetastatic HER2-Negative Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaNCT05770531Vanderbilt-Ingram Cancer Center160
招募中
2 期
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast CancerTriple Negative Breast CancerBreast CancerNCT04768426Stanford University40
进行中（未招募）
2 期
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After SurgeryColon AdenocarcinomaStage IIA Colon Cancer AJCC v8NCT04068103NRG Oncology635
已完成
不适用
Circulating Tumor Cells in Non-Small Cell Lung CarcinomaPrimary Lung CancerNCT01830426Epic Sciences232
Enrolling By Invitation
1 期
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic RetinoblastomaHigh-risk NeuroblastomaRetinoblastomaRefractory NeuroblastomaRelapsed NeuroblastomaNCT05650749Stephan Grupp MD PhD45